Association of integrated biomarkers and progression-free survival prediction in patients with gastroenteropancreatic neuroendocrine tumors undergoing [177Lu]Lu-DOTA-TATE therapy
Year: 2025
Type: article
Study design: Observational Study
Abstract: Integrated biomarkers that predict survival in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NET) receiving peptide receptor radionuclide therapy (PRRT) are still limited.This study aims to identify predictors of progression-free survival (PFS) in patients with GEP-NET undergoing two cycles of PRRT.Methods: This single-center retrospective study included 178 patients with GEP-NET (G1 and G2) who received at least two consecutive cycles of PRRT with [177Lu]Lu-DOTA-TATE and underwent somatostatin receptor (SSTR)-PET/CT before and after therapy.At baseline, Krenning score (KS) > 2, clinical, pathological and laboratory parameters were collected and correlated to PFS.Survival predictors were analyzed using univariate and multivariate models.For goodness-of-fit analysis, the Akaike information criterion and Harrell concordance index were determined.To determine the impact on the regression model the Wald-Test was performed.Results: In univariate analysis, KS 3 (vs.KS 4; HR, 2.02; 95% CI, 1.27-3.22;p = 0.012), Ki-67 > 5 % (HR, 2.00; 95% CI, 1.31-3.04;p = 0.008), CgA > 200 ng/mL (HR, 1.77; 95% CI, 1.14-2.76;p = 0.027) and NSE > 35 ng/mL (HR, 2.37; 95% CI, 1.44-3.89;p < 0.008) were significantly associated with shorter PFS, with CgA providing the highest C-index (0.6).In multivariate analysis , KS 3 (vs.KS 4; HR, 1.94; 95% CI, 1.17-3.21;p = 0.01), CgA > 200 ng/mL (HR, 1.76; CI, 1.08-2.87;p = 0.024), NSE > 35 ng/mL (HR, 1.98; 95% CI, 1.17-3.36;p = 0.011), and Ki-67 > 5 % (HR, 1.89; 95% CI, 1.18-3.02;p = 0.008) were significantly associated with reduced PFS.Including KS into multivariate analysis significantly improved the Cox regression model performance, as shown by a reduction in Akaike Information Criterion (592/596) and an increase in concordance index (0.66/0.65).The Wald test for individual variables supported the significance of both Ki-67 (7.1) and KS (6.7) as independent predictors of PFS.Conclusions: NSE, CgA, KS and Ki-67 emerged as independent predictors of PFS in GEP-NET patients scheduled for two cycles of PRRT, thereby emphasizing the importance of integrated diagnostics including in-and ex-vivo biomarkers to identify high-risk individuals prone to disease progression.
Source: Theranostics
DOI: 10.7150/thno.112588
Authors: Felix L. Herr, Christian Dascalescu, Ricarda Ebner, Moritz L. Schnitzer, Matthias P. Fabritius, Christine Schmid-Tannwald, Mathias J. Zacherl, Vera Wenter, Lena M. Unterrainer, Matthias Brendel, Adrien Holzgreve, Rudolf A. Werner, Christoph J. Auernhammer, Christine Spitzweg, Thomas Knösel, Tanja Burkard, Jens Ricke, Maurice M. Heimer, Gabriel T. Sheikh, Clemens C. Cyran
Institutions: LMU Klinikum, Ludwig-Maximilians-Universität München, German Cancer Research Center, German Center for Neurodegenerative Diseases, Munich Cluster for Systems Neurology, Deutsches Konsortium für Translationale Krebsforschung, Johns Hopkins University, Johns Hopkins Medicine, European Neuroendocrine Tumor Society
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,671
OpenAlex ID: W4411195847
